Floxuridine (FUdR)

An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Also Known As:

Networked: 571 relevant articles (54 outcomes, 93 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Wataya, Yusuke: 9 articles (04/2014 - 01/2002)
2.	Kim, Hye-Sook: 9 articles (04/2014 - 01/2002)
3.	Xiang, Yang: 8 articles (08/2014 - 08/2003)
4.	Sato, Akira: 8 articles (04/2014 - 01/2006)
5.	Hiramoto, Akiko: 8 articles (04/2014 - 01/2006)
6.	Satake, Akito: 8 articles (04/2014 - 01/2006)
7.	Fong, Yuman: 7 articles (02/2013 - 08/2005)
8.	Jarnagin, William R: 6 articles (02/2013 - 07/2009)
9.	Kemeny, Nancy E: 6 articles (02/2013 - 05/2009)
10.	Kemeny, N: 6 articles (09/2009 - 06/2000)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 02/01/1999 - "Improved results with high response rates have been reported after development of intra-arterial (i.a.) long-term regimens with FUdR in patients with colorectal liver metastases using implantable pumps and ports. " 02/01/1992 - "In contrast, delayed HA FUdR infusion controlled hepatic metastases (P = 0.04) and improved survival (P < 0.05)." 06/01/2014 - "The 1-, 3-, and 5-year survival rates after metastasis were 97%, 49%, and 26% for the ablation group, and 72%, 24%, and 24% for the FUDR group, respectively. " 06/01/2014 - "Patients in the two groups were matched by sex, age, number of metastases, and calendar year of RFA or FUDR. " 04/01/2002 - "HA FUDR delivery via an implanted system in the treatment of colorectal liver metastases represents the largest application of HA therapy and provides a basis for future advances when combined with other regional and systemic treatments."
2.	Colorectal Neoplasms (Colorectal Cancer) 12/01/1990 - "Because of the limited chemosensitivity of metastatic colorectal tumor cells to FUdR in vitro, we postulate that other mechanisms besides direct cytotoxicity contribute to the clinical efficacy of FUdR in vivo." 12/01/1990 - "In this study, the direct cytotoxic effect of FUdR was measured on ten metastatic and two primary-site colorectal carcinomas in a primary culture assay system. " 08/01/1990 - "Based on these data, we cannot recommend treatment with intra-arterial floxuridine as given in this study for metastatic colorectal cancer to the liver." 11/01/1989 - "A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial." 08/01/2005 - "Combination therapy with HAI FUDR and Dex plus systemic Oxal combinations may be safely administered to patients with colorectal cancer. "
3.	Neoplasms (Cancer) 08/01/1991 - "More importantly, the tumor/liver ratio of FUDR uptake was significantly greater in the HA/A-II group (3.40) than that in the HA without A-II (0.98) group (P less than 0.001). " 08/01/1991 - "Hepatic artery infusions, both with and without A-II, resulted in a significantly greater tumor uptake of FUDR than the iv infusions (P less than 0.001). " 01/01/1989 - "Hepatic artery infusion resulted in a significantly improved tumor-to-liver ratio of FUDR uptake (p less than 0.001). " 11/01/1986 - "A pilot study was designed to evaluate the efficacy of high-dose FUDR administered through the hepatic artery for the treatment of cancer involving the liver. " 01/01/1986 - "A significant reduction of tumor growth was observed only after continuous infusion of FUDR via the hepatic artery. "
4.	Renal Cell Carcinoma (Grawitz Tumor) 05/15/1995 - "Continuous infusion of 2'-deoxy-5-fluorouridine (FUdR) has shown promise in its activity against metastatic renal cell carcinoma. " 08/01/1996 - "In this study FUDR + alpha 2b-IFN demonstrated interesting activity in metastatic renal cell carcinoma, showing promise also in patients with unfavourable prognostic characteristics. " 08/01/1996 - "The main purpose of this phase II study was to assess the activity and toxic effects of a combination of FUDR and alpha 2b-IFN in metastatic renal cell carcinoma. " 01/01/1995 - "The CADD-Micro System (Sims Deltec, St. Paul, MN) was formally evaluated in patients with metastatic renal cell cancer, participating in a phase-III study comparing a 2-week circadian versus flat infusion of FUDR. " 06/01/1993 - "A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma."
5.	Trophoblastic Neoplasms (Trophoblastic Tumor) 06/01/2004 - "Floxuridine-containing regimens in the treatment of gestational trophoblastic tumor." 08/01/2003 - "[Floxuridine-containing regime in the treatment of gestational trophoblastic tumor]." 11/01/2004 - "Forty gestational trophoblastic tumor (GTT) patients were treated with 30 mg/kg of 5-FU or prodrug FUDR during a 10-day cycle. " 08/01/2003 - "Seventy-four patients with gestational trophoblastic tumors (GTT), 47 invasive mole and 27 choriocarcinoma, were treated with FUDR-containing regime. " 06/01/2004 - "To analyze the efficacy of floxuridine (FUDR)-containing regimens in the treatment of gestational trophoblastic tumor (GTT). "

Related Drugs and Biologics

1.	Floxuridine (FUdR)
2.	Fluorouracil (Carac)
3.	irinotecan (Camptosar)
4.	oxaliplatin (Eloxatin)
5.	Leucovorin (Folinic Acid)
6.	Dexamethasone (Maxidex)
7.	Mitomycin (Mitomycin-C)
8.	Etoposide (VP 16)
9.	Vincristine (Oncovin)
10.	Dactinomycin (Ac-De)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Infusion Pumps (Infusion Pump)
3.	Laparotomy
4.	Intra-Arterial Infusions
5.	Catheters